SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-059791
Filing Date
2023-11-07
Accepted
2023-11-07 08:31:41
Documents
14
Period of Report
2023-11-07
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K inzy-20231107.htm   iXBRL 8-K 48143
2 EX-99.1 inzy-ex99_1.htm EX-99.1 172005
3 GRAPHIC img4202433_0.jpg GRAPHIC 8171
  Complete submission text file 0000950170-23-059791.txt   365480

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT inzy-20231107.xsd EX-101.SCH 2466
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT inzy-20231107_pre.xml EX-101.PRE 10228
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT inzy-20231107_lab.xml EX-101.LAB 13904
8 EXTRACTED XBRL INSTANCE DOCUMENT inzy-20231107_htm.xml XML 4880
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 231381816
SIC: 2834 Pharmaceutical Preparations